{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T22:20:50Z","timestamp":1792794050631,"version":"4.5.0"},"reference-count":59,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2022,7,6]],"date-time":"2022-07-06T00:00:00Z","timestamp":1657065600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,7,6]],"date-time":"2022-07-06T00:00:00Z","timestamp":1657065600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001593","name":"Irish Cancer Society","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001593","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100010665","name":"H2020 Marie Sk\u0142odowska-Curie Actions","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100010665","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Human Cell"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>The IGROVCDDP cisplatin-resistant ovarian cancer cell line is an unusual model, as it is also cross-resistant to paclitaxel. IGROVCDDP, therefore, models the resistance phenotype of serous ovarian cancer patients who have failed frontline platinum\/taxane chemotherapy. IGROVCDDP has also undergone epithelial-mesenchymal transition (EMT). We aim to determine if alterations in EMT-related genes are related to or independent from the drug-resistance phenotypes. EMT gene and protein markers, invasion, motility and morphology were investigated in IGROVCDDP and its parent drug-sensitive cell line IGROV-1. <jats:italic>ZEB1<\/jats:italic> was investigated by qPCR, Western blotting and siRNA knockdown. <jats:italic>ZEB1<\/jats:italic> was also investigated in publicly available ovarian cancer gene-expression datasets. IGROVCDDP cells have decreased protein levels of epithelial marker E-cadherin (6.18-fold, <jats:italic>p<\/jats:italic>\u2009=\u20091.58e\u221204) and higher levels of mesenchymal markers vimentin (2.47-fold, <jats:italic>p<\/jats:italic>\u2009=\u20094.43e\u221203), N-cadherin (4.35-fold, <jats:italic>p<\/jats:italic>\u2009=\u20094.76e\u221203) and ZEB1 (3.43-fold, <jats:italic>p<\/jats:italic>\u2009=\u20090.04). IGROVCDDP have a spindle-like morphology consistent with EMT. Knockdown of <jats:italic>ZEB1<\/jats:italic> in IGROVCDDP does not lead to cisplatin sensitivity but shows a reversal of EMT-gene signalling and an increase in cell circularity. High <jats:italic>ZEB1<\/jats:italic> gene expression (HR\u2009=\u20091.31, <jats:italic>n<\/jats:italic>\u2009=\u20092051, <jats:italic>p<\/jats:italic>\u2009=\u20091.31e\u221205) is a marker of poor overall survival in high-grade serous ovarian-cancer patients. In contrast, <jats:italic>ZEB1<\/jats:italic> is not predictive of overall survival in high-grade serous ovarian-cancer patients known to be treated with platinum chemotherapy. The increased expression of <jats:italic>ZEB1<\/jats:italic> in IGROVCDDP appears to be independent of the drug-resistance phenotypes. <jats:italic>ZEB1<\/jats:italic> has the potential to be used as biomarker of overall prognosis in ovarian-cancer patients but not of platinum\/taxane chemoresistance.<\/jats:p>","DOI":"10.1007\/s13577-022-00744-y","type":"journal-article","created":{"date-parts":[[2022,7,7]],"date-time":"2022-07-07T01:02:46Z","timestamp":1657155766000},"page":"1547-1559","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["The EMT-activator ZEB1 is unrelated to platinum drug resistance in ovarian cancer but is predictive of survival"],"prefix":"10.1007","volume":"35","author":[{"given":"Sophie","family":"Rae","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cathy","family":"Spillane","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gordon","family":"Blackshields","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen F.","family":"Madden","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joanne","family":"Keenan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7892-951X","authenticated-orcid":false,"given":"Britta","family":"Stordal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,7,6]]},"reference":[{"key":"744_CR1","first-page":"163","volume":"39","author":"EL Low","year":"2013","unstructured":"Low EL, Waller J, Menon U, et al. Ovarian cancer symptom awareness and anticipated time to help-seeking for symptoms among UK women. J FamPlannReprod Health Care. 2013;39:163\u201371.","journal-title":"J FamPlannReprod Health Care"},{"key":"744_CR2","unstructured":"Office for National Statistics. Cancer survival in England\u2014adults diagnosed. 2022."},{"key":"744_CR3","doi-asserted-by":"publisher","first-page":"1240","DOI":"10.1016\/S0140-6736(18)32552-2","volume":"393","author":"S Lheureux","year":"2019","unstructured":"Lheureux S, Gourley C, Vergote I, Oza AM. Epithelial ovarian cancer. Lancet Lond Engl. 2019;393:1240\u201353. https:\/\/doi.org\/10.1016\/S0140-6736(18)32552-2.","journal-title":"Lancet Lond Engl"},{"key":"744_CR4","doi-asserted-by":"publisher","first-page":"1371","DOI":"10.1016\/S0140-6736(09)61338-6","volume":"374","author":"BT Hennessy","year":"2009","unstructured":"Hennessy BT, Coleman RL, Markman M. Ovarian cancer. Lancet. 2009;374:1371\u201382.","journal-title":"Lancet"},{"key":"744_CR5","doi-asserted-by":"publisher","first-page":"e40717","DOI":"10.1371\/journal.pone.0040717","volume":"7","author":"B Stordal","year":"2012","unstructured":"Stordal B, Hamon M, McEneaney V, et al. Resistance to paclitaxel in a cisplatin-resistant ovarian cancer cell line is mediated by P-glycoprotein. PLoS\u00a0One. 2012;7:e40717.","journal-title":"PLoS\u00a0One"},{"key":"744_CR6","first-page":"277","volume":"31","author":"H Kajiyama","year":"2007","unstructured":"Kajiyama H, Shibata K, Terauchi M, et al. Chemoresistance to paclitaxel induces epithelial-mesenchymal transition and enhances metastatic potential for epithelial ovarian carcinoma cells. Int J Oncol. 2007;31:277\u201383.","journal-title":"Int J Oncol"},{"key":"744_CR7","doi-asserted-by":"publisher","first-page":"268","DOI":"10.2174\/156800910791190175","volume":"10","author":"N Ahmed","year":"2010","unstructured":"Ahmed N, Abubaker K, Findlay J, Quinn M. Epithelial mesenchymal transition and cancer stem cell-like phenotypes facilitate chemoresistance in recurrent ovarian cancer. Curr Cancer Drug Targets. 2010;10:268\u201378.","journal-title":"Curr Cancer Drug Targets"},{"key":"744_CR8","doi-asserted-by":"publisher","first-page":"104","DOI":"10.3390\/cancers9080104","volume":"9","author":"Y Klymenko","year":"2017","unstructured":"Klymenko Y, Kim O, Stack MS. Complex determinants of epithelial: mesenchymal phenotypic plasticity in ovarian cancer. Cancers. 2017;9:104. https:\/\/doi.org\/10.3390\/cancers9080104.","journal-title":"Cancers"},{"key":"744_CR9","doi-asserted-by":"publisher","first-page":"2350","DOI":"10.1158\/1078-0432.CCR-10-2325","volume":"17","author":"L Rosano","year":"2011","unstructured":"Rosano L, Cianfrocca R, Spinella F, et al. Acquisition of chemoresistance and EMT Phenotype is linked with activation of the endothelin A receptor pathway in ovarian carcinoma cells. Clin Cancer Res. 2011;17:2350\u201360.","journal-title":"Clin Cancer Res"},{"key":"744_CR10","doi-asserted-by":"publisher","first-page":"2309","DOI":"10.1038\/onc.2011.409","volume":"31","author":"P Yue","year":"2012","unstructured":"Yue P, Zhang X, Paladino D, et al. Hyperactive EGF receptor, Jaks and Stat3 signaling promote enhanced colony-forming ability, motility and migration of cisplatin-resistant ovarian cancer cells. Oncogene. 2012;31:2309\u201322.","journal-title":"Oncogene"},{"key":"744_CR11","doi-asserted-by":"publisher","first-page":"4906","DOI":"10.1038\/s41388-021-01891-6","volume":"40","author":"J Zhang","year":"2021","unstructured":"Zhang J, Guan W, Xu X, et al. A novel homeostatic loop of sorcin drives paclitaxel-resistance and malignant progression via Smad4\/ZEB1\/miR-142-5p in human ovarian cancer. Oncogene. 2021;40:4906\u201318. https:\/\/doi.org\/10.1038\/s41388-021-01891-6.","journal-title":"Oncogene"},{"key":"744_CR12","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1002\/jcp.21240","volume":"213","author":"N Ahmed","year":"2007","unstructured":"Ahmed N, Thompson EW, Quinn MA. Epithelial-mesenchymal interconversions in normal ovarian surface epithelium and ovarian carcinomas: an exception to the norm. J Cell Physiol. 2007;213:581\u20138.","journal-title":"J Cell Physiol"},{"key":"744_CR13","doi-asserted-by":"publisher","first-page":"643","DOI":"10.1007\/s10585-008-9171-5","volume":"25","author":"LG Hudson","year":"2008","unstructured":"Hudson LG, Zeineldin R, Stack MS. Phenotypic plasticity of neoplastic ovarian epithelium: unique cadherin profiles in tumor progression. Clin Exp Metastasis. 2008;25:643\u201355.","journal-title":"Clin Exp Metastasis"},{"key":"744_CR14","doi-asserted-by":"publisher","first-page":"1357","DOI":"10.1097\/IGC.0b013e3182a5e760","volume":"23","author":"D Chen","year":"2013","unstructured":"Chen D, Wang J, Zhang Y, et al. Effect of down-regulated transcriptional repressor ZEB1 on the epithelial-mesenchymal transition of ovarian cancer cells. Int J Gynecol Cancer. 2013;23:1357\u201366.","journal-title":"Int J Gynecol Cancer"},{"key":"744_CR15","doi-asserted-by":"publisher","first-page":"671","DOI":"10.1038\/nmeth.2089","volume":"9","author":"CA Schneider","year":"2012","unstructured":"Schneider CA, Rasband WS, Eliceiri KW. NIH Image to ImageJ: 25 years of image analysis. Nat Methods. 2012;9:671\u20135. https:\/\/doi.org\/10.1038\/nmeth.2089.","journal-title":"Nat Methods"},{"key":"744_CR16","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1007\/s002800050727","volume":"41","author":"J Ma","year":"1998","unstructured":"Ma J, Maliepaard M, Kolker HJ, et al. Abrogated energy-dependent uptake of cisplatin in a cisplatin-resistant subline of the human ovarian cancer cell line IGROV-1. Cancer Chemother Pharmacol. 1998;41:186\u201392.","journal-title":"Cancer Chemother Pharmacol"},{"key":"744_CR17","first-page":"658","volume":"29","author":"KJ Himmelstein","year":"1981","unstructured":"Himmelstein KJ, Patton TF, Belt RJ, et al. Clinical kinetics of intact cisplatin and some related species. ClinPharmTher. 1981;29:658\u201364.","journal-title":"ClinPharmTher"},{"key":"744_CR18","doi-asserted-by":"publisher","first-page":"376","DOI":"10.1007\/BF00257446","volume":"24","author":"SS Bielack","year":"1989","unstructured":"Bielack SS, Erttmann R, Looft G, et al. Platinum disposition after intraarterial and intravenous infusion of cisplatin for osteosarcoma. Cooperative Osteosarcoma Study Group COSS. Cancer Chemother Pharmacol. 1989;24:376\u201380. https:\/\/doi.org\/10.1007\/BF00257446.","journal-title":"Cancer Chemother Pharmacol"},{"key":"744_CR19","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1038\/nrc2131","volume":"7","author":"H Peinado","year":"2007","unstructured":"Peinado H, Olmeda D, Cano A. Snail, Zeb and bHLH factors in tumour progression: an alliance against the epithelial phenotype? Nat Rev Cancer. 2007;7:415\u201328.","journal-title":"Nat Rev Cancer"},{"key":"744_CR20","doi-asserted-by":"publisher","first-page":"262","DOI":"10.1159\/000493864","volume":"63","author":"Y Cui","year":"2018","unstructured":"Cui Y, Qin L, Tian D, et al. ZEB1 promotes chemoresistance to cisplatin in ovarian cancer cells by suppressing SLC3A2. Chemotherapy. 2018;63:262\u201371. https:\/\/doi.org\/10.1159\/000493864.","journal-title":"Chemotherapy"},{"key":"744_CR21","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1016\/j.gene.2019.03.043","volume":"700","author":"M Wang","year":"2019","unstructured":"Wang M, Zhang R, Zhang S, et al. MicroRNA-574-3p regulates epithelial mesenchymal transition and cisplatin resistance via targeting ZEB1 in human gastric carcinoma cells. Gene. 2019;700:110\u20139. https:\/\/doi.org\/10.1016\/j.gene.2019.03.043.","journal-title":"Gene"},{"key":"744_CR22","doi-asserted-by":"publisher","first-page":"2386","DOI":"10.12659\/MSM.915866","volume":"25","author":"Z Deng","year":"2019","unstructured":"Deng Z, Wang H, Guo G, et al. Next-generation sequencing analysis of mRNA profile in cisplatin-resistant gastric cancer cell line SGC7901. Med Sci Monit Int Med J Exp Clin Res. 2019;25:2386\u201396. https:\/\/doi.org\/10.12659\/MSM.915866.","journal-title":"Med Sci Monit Int Med J Exp Clin Res"},{"key":"744_CR23","doi-asserted-by":"publisher","first-page":"1006","DOI":"10.5732\/cjc.010.10236","volume":"29","author":"Y Chen","year":"2010","unstructured":"Chen Y, Zuo J, Liu Y, et al. Inhibitory effects of miRNA-200c on chemotherapy-resistance and cell proliferation of gastric cancer SGC7901\/DDP cells. Chin J Cancer. 2010;29:1006\u201311. https:\/\/doi.org\/10.5732\/cjc.010.10236.","journal-title":"Chin J Cancer"},{"key":"744_CR24","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1007\/s12253-013-9664-7","volume":"20","author":"L Chang","year":"2014","unstructured":"Chang L, Guo F, Wang Y, et al. MicroRNA-200c regulates the sensitivity of chemotherapy of gastric cancer SGC7901\/DDP cells by directly targeting RhoE. Pathol Oncol Res POR. 2014;20:93\u20138. https:\/\/doi.org\/10.1007\/s12253-013-9664-7.","journal-title":"Pathol Oncol Res POR"},{"key":"744_CR25","first-page":"1163","volume":"17","author":"X-D Yan","year":"2007","unstructured":"Yan X-D, Li M, Yuan Y, et al. Biological comparison of ovarian cancer resistant cell lines to cisplatin and taxol by two different administrations. Oncol Rep. 2007;17:1163\u20139.","journal-title":"Oncol Rep"},{"key":"744_CR26","doi-asserted-by":"publisher","first-page":"99482","DOI":"10.18632\/oncotarget.20107","volume":"8","author":"J Sakata","year":"2017","unstructured":"Sakata J, Utsumi F, Suzuki S, et al. Inhibition of ZEB1 leads to inversion of metastatic characteristics and restoration of paclitaxel sensitivity of chronic chemoresistant ovarian carcinoma cells. Oncotarget. 2017;8:99482\u201394. https:\/\/doi.org\/10.18632\/oncotarget.20107.","journal-title":"Oncotarget"},{"key":"744_CR27","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1016\/j.canlet.2010.09.007","volume":"300","author":"RM Gemmill","year":"2011","unstructured":"Gemmill RM, Roche J, Potiron VA, et al. ZEB1-responsive genes in non-small cell lung cancer. Cancer Lett. 2011;300:66\u201378.","journal-title":"Cancer Lett"},{"key":"744_CR28","first-page":"4970","volume":"45","author":"J Benard","year":"1985","unstructured":"Benard J, Da Silva J, De Blois MC, et al. Characterization of a human ovarian adenocarcinoma line, IGROV1, in tissue culture and in nude mice. Cancer Res. 1985;45:4970\u20139.","journal-title":"Cancer Res"},{"key":"744_CR29","doi-asserted-by":"publisher","first-page":"733","DOI":"10.1016\/j.ajpath.2015.11.011","volume":"186","author":"RJ Kurman","year":"2016","unstructured":"Kurman RJ, Shih I-M. The dualistic model of ovarian carcinogenesis: revisited, revised, and expanded. Am J Pathol. 2016;186:733\u201347. https:\/\/doi.org\/10.1016\/j.ajpath.2015.11.011.","journal-title":"Am J Pathol"},{"key":"744_CR30","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1038\/modpathol.2011.183","volume":"25","author":"RA Soslow","year":"2012","unstructured":"Soslow RA, Han G, Park KJ, et al. Morphologic patterns associated with BRCA1 and BRCA2 genotype in ovarian carcinoma. Mod Pathol. 2012;25:625\u201336. https:\/\/doi.org\/10.1038\/modpathol.2011.183.","journal-title":"Mod Pathol"},{"key":"744_CR31","doi-asserted-by":"publisher","first-page":"2126","DOI":"10.1038\/ncomms3126","volume":"4","author":"S Domcke","year":"2013","unstructured":"Domcke S, Sinha R, Levine DA, et al. Evaluating cell lines as tumour models by comparison of genomic profiles. Nat Commun. 2013;4:2126. https:\/\/doi.org\/10.1038\/ncomms3126.","journal-title":"Nat Commun"},{"key":"744_CR32","doi-asserted-by":"publisher","first-page":"7911","DOI":"10.1200\/JCO.2005.02.9363","volume":"23","author":"D Spentzos","year":"2005","unstructured":"Spentzos D, Levine DA, Kolia S, et al. Unique gene expression profile based on pathologic response in epithelial ovarian cancer. J Clin Oncol. 2005;23:7911\u20138.","journal-title":"J Clin Oncol"},{"key":"744_CR33","doi-asserted-by":"publisher","first-page":"5478","DOI":"10.1158\/0008-5472.CAN-07-6595","volume":"68","author":"T Bonome","year":"2008","unstructured":"Bonome T, Levine DA, Shih J, et al. A gene signature predicting for survival in suboptimally debulked patients with ovarian cancer. Cancer Res. 2008;68:5478\u201386.","journal-title":"Cancer Res"},{"key":"744_CR34","doi-asserted-by":"publisher","first-page":"e1000024","DOI":"10.1371\/journal.pmed.1000024","volume":"6","author":"APG Crijns","year":"2009","unstructured":"Crijns APG, Fehrmann RSN, de Jong S, et al. Survival-related profile, pathways, and transcription factors in ovarian cancer. PLoS Med. 2009;6:e1000024.","journal-title":"PLoS Med"},{"key":"744_CR35","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1002\/path.2547","volume":"218","author":"C Denkert","year":"2009","unstructured":"Denkert C, Budczies J, Darb-Esfahani S, et al. A prognostic gene expression index in ovarian cancer\u2014validation across different independent data sets. J Pathol. 2009;218:273\u201380.","journal-title":"J Pathol"},{"key":"744_CR36","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1016\/j.ccr.2009.10.018","volume":"16","author":"SC Mok","year":"2009","unstructured":"Mok SC, Bonome T, Vathipadiekal V, et al. A gene signature predictive for outcome in advanced ovarian cancer identifies a survival factor: microfibril-associated glycoprotein 2. Cancer Cell. 2009;16:521\u201332.","journal-title":"Cancer Cell"},{"key":"744_CR37","doi-asserted-by":"publisher","first-page":"e9615","DOI":"10.1371\/journal.pone.0009615","volume":"5","author":"K Yoshihara","year":"2010","unstructured":"Yoshihara K, Tajima A, Yahata T, et al. Gene expression profile for predicting survival in advanced-stage serous ovarian cancer across two independent datasets. PLoS\u00a0One. 2010;5:e9615.","journal-title":"PLoS\u00a0One"},{"key":"744_CR38","doi-asserted-by":"publisher","first-page":"1374","DOI":"10.1158\/1078-0432.CCR-11-2725","volume":"18","author":"K Yoshihara","year":"2012","unstructured":"Yoshihara K, Tsunoda T, Shigemizu D, et al. High-risk ovarian cancer based on 126-gene expression signature is uniquely characterized by downregulation of antigen presentation pathway. Clin Cancer Res. 2012;18:1374\u201385.","journal-title":"Clin Cancer Res"},{"key":"744_CR39","doi-asserted-by":"publisher","first-page":"e18202","DOI":"10.1371\/journal.pone.0018202","volume":"6","author":"PA Konstantinopoulos","year":"2011","unstructured":"Konstantinopoulos PA, Cannistra SA, Fountzilas H, et al. Integrated analysis of multiple microarray datasets identifies a reproducible survival predictor in ovarian cancer. PLoS\u00a0One. 2011;6:e18202.","journal-title":"PLoS\u00a0One"},{"key":"744_CR40","doi-asserted-by":"publisher","first-page":"e30550","DOI":"10.1371\/journal.pone.0030550","volume":"7","author":"JS Ferriss","year":"2012","unstructured":"Ferriss JS, Kim Y, Duska L, et al. Multi-gene expression predictors of single drug responses to adjuvant chemotherapy in ovarian carcinoma: predicting platinum resistance. PLoS\u00a0One. 2012;7:e30550.","journal-title":"PLoS\u00a0One"},{"key":"744_CR41","unstructured":"The Cancer Genome Atlas. 2013."},{"key":"744_CR42","doi-asserted-by":"publisher","first-page":"5198","DOI":"10.1158\/1078-0432.CCR-08-0196","volume":"14","author":"RW Tothill","year":"2008","unstructured":"Tothill RW, Tinker AV, George J, et al. Novel molecular subtypes of serous and endometrioid ovarian cancer linked to clinical outcome. Clin Cancer Res. 2008;14:5198\u2013208.","journal-title":"Clin Cancer Res"},{"key":"744_CR43","doi-asserted-by":"publisher","first-page":"3555","DOI":"10.1200\/JCO.2009.27.5719","volume":"28","author":"PA Konstantinopoulos","year":"2010","unstructured":"Konstantinopoulos PA, Spentzos D, Karlan BY, et al. Gene expression profile of BRCAness that correlates with responsiveness to chemotherapy and with outcome in patients with epithelial ovarian cancer. J Clin Oncol. 2010;28:3555\u201361.","journal-title":"J Clin Oncol"},{"key":"744_CR44","doi-asserted-by":"publisher","first-page":"18","DOI":"10.3892\/mco.2015.662","volume":"4","author":"X Li","year":"2016","unstructured":"Li X, Huang R, Li RH, et al. Expression of zinc finger E-box-binding homeobox factor 1 in epithelial ovarian cancer: a clinicopathological analysis of 238 patients. Mol Clin Oncol. 2016;4:18\u201322. https:\/\/doi.org\/10.3892\/mco.2015.662.","journal-title":"Mol Clin Oncol"},{"key":"744_CR45","doi-asserted-by":"publisher","first-page":"326","DOI":"10.1007\/s004320050177","volume":"124","author":"M Markman","year":"1998","unstructured":"Markman M, Kennedy A, Webster K, et al. Evidence that a \u201ctreatment-free interval of less than 6 months\u201d does not equate with clinically defined platinum resistance in ovarian cancer or primary peritoneal carcinoma. J Cancer Res Clin Oncol. 1998;124:326\u20138.","journal-title":"J Cancer Res Clin Oncol"},{"key":"744_CR46","doi-asserted-by":"publisher","first-page":"11","DOI":"10.2217\/fon-2017-0317","volume":"13","author":"A Poveda","year":"2017","unstructured":"Poveda A, Marth C. Platinum or nonplatinum in recurrent ovarian cancer: that is the question. Future Oncol Lond Engl. 2017;13:11\u20136. https:\/\/doi.org\/10.2217\/fon-2017-0317.","journal-title":"Future Oncol Lond Engl"},{"key":"744_CR47","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1007\/s002800050744","volume":"41","author":"J Ma","year":"1998","unstructured":"Ma J, Maliepaard M, Nooter K, et al. Synergistic cytotoxicity of cisplatin and topotecan or SN-38 in a panel of eight solid-tumor cell lines in vitro. Cancer Chemother Pharmacol. 1998;41:307\u201316.","journal-title":"Cancer Chemother Pharmacol"},{"key":"744_CR48","doi-asserted-by":"publisher","first-page":"929","DOI":"10.1038\/nprot.2010.43","volume":"5","author":"L Young","year":"2010","unstructured":"Young L, Sung J, Stacey G, Masters JR. Detection of Mycoplasma in cell cultures. Nat Protoc. 2010;5:929\u201334.","journal-title":"Nat Protoc"},{"key":"744_CR49","unstructured":"Affymetrix. Quality assessment of exon and gene arrays. Affymetrix genechip gene and exon array white paper collection, 2018."},{"key":"744_CR50","doi-asserted-by":"publisher","first-page":"2363","DOI":"10.1093\/bioinformatics\/btq431","volume":"26","author":"BS Carvalho","year":"2010","unstructured":"Carvalho BS, Irizarry RA. A framework for oligonucleotide microarray preprocessing. Bioinformatics. 2010;26:2363\u20137.","journal-title":"Bioinformatics"},{"key":"744_CR51","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1093\/bioinformatics\/19.2.185","volume":"19","author":"BM Bolstad","year":"2003","unstructured":"Bolstad BM, Irizarry RA, Astrand M, Speed TP. A comparison of normalization methods for high density oligonucleotide array data based on variance and bias. Bioinformatics. 2003;19:185\u201393.","journal-title":"Bioinformatics"},{"key":"744_CR52","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1093\/biostatistics\/4.2.249","volume":"4","author":"RA Irizarry","year":"2003","unstructured":"Irizarry RA, Hobbs B, Collin F, et al. Exploration, normalization, and summaries of high density oligonucleotide array probe level data. Biostatistics. 2003;4:249\u201364.","journal-title":"Biostatistics"},{"key":"744_CR53","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1016\/j.febslet.2004.07.055","volume":"573","author":"R Breitling","year":"2004","unstructured":"Breitling R, Armengaud P, Amtmann A, Herzyk P. Rank products: a simple, yet powerful, new method to detect differentially regulated genes in replicated microarray experiments. FEBS Lett. 2004;573:83\u201392.","journal-title":"FEBS Lett"},{"key":"744_CR54","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1186\/1471-2105-7-359","volume":"7","author":"IB Jeffery","year":"2006","unstructured":"Jeffery IB, Higgins DG, Culhane AC. Comparison and evaluation of methods for generating differentially expressed gene lists from microarray data. BMC Bioinform. 2006;7:359.","journal-title":"BMC Bioinform"},{"key":"744_CR55","unstructured":"Smith CA. annaffy: Annotation tools for Affymetrix biological metadata. R package version 1.30.0. 2010."},{"key":"744_CR56","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1007\/BF02905254","volume":"4","author":"A Albini","year":"1998","unstructured":"Albini A. Tumor and endothelial cell invasion of basement membranes. The matrigel chemoinvasion assay as a tool for dissecting molecular mechanisms. Pathol Oncol Res. 1998;4:230\u201341.","journal-title":"Pathol Oncol Res"},{"key":"744_CR57","first-page":"1101","volume":"3","author":"TD Schmittgen","year":"2008","unstructured":"Schmittgen TD, Livak KJ. Analyzing real-time PCR data by the comparative CT method. NatProtocols. 2008;3:1101\u20138.","journal-title":"NatProtocols"},{"key":"744_CR58","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1186\/1476-4598-13-241","volume":"13","author":"SF Madden","year":"2014","unstructured":"Madden SF, Clarke C, Stordal B, et al. OvMark: a user-friendly system for the identification of prognostic biomarkers in publically available ovarian cancer gene expression datasets. Mol Cancer. 2014;13:241.","journal-title":"Mol Cancer"},{"key":"744_CR59","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1038\/nature10166","volume":"474","author":"Cancer Genome Atlas Research Network","year":"2011","unstructured":"Cancer Genome Atlas Research Network. Integrated genomic analyses of ovarian carcinoma. Nature. 2011;474:609\u201315.","journal-title":"Nature"}],"container-title":["Human Cell"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13577-022-00744-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13577-022-00744-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13577-022-00744-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,8,12]],"date-time":"2022-08-12T17:13:38Z","timestamp":1660324418000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s13577-022-00744-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,7,6]]},"references-count":59,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2022,9]]}},"alternative-id":["744"],"URL":"https:\/\/doi.org\/10.1007\/s13577-022-00744-y","relation":{},"ISSN":["1749-0774"],"issn-type":[{"value":"1749-0774","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,7,6]]},"assertion":[{"value":"19 April 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 June 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 July 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors have no conflicts of interest to declare.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}